A Phase 3 interventional study of Apixaban and Unfractionated Heparin (UFH) in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by Pfizer. Completed at 20 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-06-23.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.
Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 20th largest by enrollment, is the only one that started in 2013, is one of 10 in phase 3, and was the 7th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Rushad Patell · Sites in United States
Ages 18+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
James Bayley · Sites in United States
Ages 18+
University Hospital, Geneva
Ages 18–120
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 10
First in 2004; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 445 across the 26 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing apixaban in Venous Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07713875James BayleyExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing apixaban in Venous Thrombosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate safety of apixaban in Japanese acute DVT/PE subjects when symptomatic DVT/PE subjects are treated with 10 mg BID apixaban for 7 days as initial therapy followed by 5 mg BID apixaban for 23 weeks as long-term therapy (total treatment period is 24 weeks)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apixaban
Drug: Unfractionated Heparin (UFH) · Drug: Warfarin
Number of Participants With Major Bleeding Events [Per International Society on Thrombosis and Homeostasis (ISTH) Definition] or Clinically Relevant Non-major (CRNM) Bleeding Events Adjudicated by Clinical Event Committee During the Treatment Period
Major bleeding event was defined as an acute clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more, a transfusion of 4 or more units of packed red blood cells (a unit of packed red blood cells equal to about 200 cc), or bleeding that occurred in critical sites (e.g. intracranial). Fatal bleeding was also defined as a major bleeding event. CRNM bleeding event was defined as an acute clinically overt bleeding that did not satisfy the definition of major bleeding and that led to either hospitalization, physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
Time frame: Baseline to Week 24
Number of Participants With Adjudicated Recurrent Symptomatic Venous Thromboembolism (VTE) [Nonfatal Deep Venous Thrombosis (DVT) or Nonfatal Pulmonary Embolism (PE)] or VTE-Related Death During the Intended Treatment Period
VTE-related death was defined as a death caused by documented PE which was diagnosed with objective testing or autopsy, or an unexplained death for which DVT/PE could not be ruled out as the cause. "Intended Treatment Period" was the period starting on the day of randomization and ending at either 2 days after the last dose of the study drug or Day 168/Week 24, whichever came late.
Time frame: Baseline to Week 24
Number of Participants With Adjudicated Thrombotic Burden Worsened in Acute Symptomatic Proximal Deep Venous Thrombosis (DVT)
Computed tomography venography (CTV) and compression ultrasound (CUS) were used to assess thrombotic burden in the participants with DVT and the results were classified as improved, no change, or worsened. The timings of CTV and CUS examinations were at Week 12 and Weeks 2, 12 and 24.
Time frame: Baseline to Week 24
Number of Participants With Adjudicated Thrombotic Burden Worsened in Acute Symptomatic Pulmonary Embolism (PE)
Computed tomography pulmonary angiography (CTPA) was used to assess thrombotic burden in the participants with PE and the results were classified as improved, no change, or worsened. The timings of CTPA examinations were Weeks 2, 12 and 24.
Time frame: Baseline to Week 24
Number of Participants With Adjudicated Major Bleeding Events [Per International Society on Thrombosis and Homeostasis (ISTH) Definition]During the Treatment Period
Major bleeding event was defined as an acute clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more, a transfusion of 4 or more units of packed red blood cells (a unit of packed red blood cells equal to about 200 cc), or bleeding that occurred in critical sites (e.g. intracranial). Fatal bleeding was also defined as a major bleeding event.
Time frame: Baseline to Week 24
Number of Participants With Adjudicated All Bleeding Events During the Treatment Periods
All bleeding events consisted of major bleeding (per Interactional Society on Thrombosis and Homeostasis [ISTH] Definition), clinically relevant non-major (CRNM) and minor bleeding. All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRMN bleeding were classified as minor bleeding.
Time frame: Baseline to Week 24
| Milestone | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| Started | 40 | 40 |
| Completed | 37 | 34 |
| Not completed | 3 | 6 |
| Withdrew: Adverse event | 0 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Request of changing hospital | 0 | 1 |
| Withdrew: Changing residence | 1 | 0 |
| Withdrew: Not receiving any study medication | 0 | 1 |
Major bleeding event was defined as an acute clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more, a transfusion of 4 or more units of packed red blood cells (a unit of packed red blood cells equal to about 200 cc), or bleeding that occurred in critical sites (e.g. intracranial). Fatal bleeding was also defined as a major bleeding event. CRNM bleeding event was defined as an acute clinically overt bleeding that did not satisfy the definition of major bleeding and that led to either hospitalization, physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
| participants | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| Number of Participants With Major Bleeding Events [Per International Society on Thrombosis and Homeostasis (ISTH) Definition] or Clinically Relevant Non-major (CRNM) Bleeding Events Adjudicated by Clinical Event Committee During the Treatment Period | 3 | 11 |
VTE-related death was defined as a death caused by documented PE which was diagnosed with objective testing or autopsy, or an unexplained death for which DVT/PE could not be ruled out as the cause. "Intended Treatment Period" was the period starting on the day of randomization and ending at either 2 days after the last dose of the study drug or Day 168/Week 24, whichever came late.
| participants | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| Number of Participants With Adjudicated Recurrent Symptomatic Venous Thromboembolism (VTE) [Nonfatal Deep Venous Thrombosis (DVT) or Nonfatal Pulmonary Embolism (PE)] or VTE-Related Death During the Intended Treatment Period | 0 | 1 |
Computed tomography venography (CTV) and compression ultrasound (CUS) were used to assess thrombotic burden in the participants with DVT and the results were classified as improved, no change, or worsened. The timings of CTV and CUS examinations were at Week 12 and Weeks 2, 12 and 24.
| participants | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| CUS - Week 2 (n=22, n=22) | 1 | 2 |
| CTV - Week 12 (n=20, n=21) | 0 | 0 |
| CUS - Week 12 (n=21, n=22) | 0 | 0 |
| CUS - Week 24 (n=20, n=22) | 0 | 1 |
Computed tomography pulmonary angiography (CTPA) was used to assess thrombotic burden in the participants with PE and the results were classified as improved, no change, or worsened. The timings of CTPA examinations were Weeks 2, 12 and 24.
| participants | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| CTPA - Week 2 (n=18, n=17) | 0 | 0 |
| CTPA - Week 12 (n=18, n=16) | 0 | 0 |
| CTPA - Week 24 (n=16, n=15) | 0 | 1 |
Major bleeding event was defined as an acute clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more, a transfusion of 4 or more units of packed red blood cells (a unit of packed red blood cells equal to about 200 cc), or bleeding that occurred in critical sites (e.g. intracranial). Fatal bleeding was also defined as a major bleeding event.
| participants | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| Number of Participants With Adjudicated Major Bleeding Events [Per International Society on Thrombosis and Homeostasis (ISTH) Definition]During the Treatment Period | 0 | 2 |
All bleeding events consisted of major bleeding (per Interactional Society on Thrombosis and Homeostasis [ISTH] Definition), clinically relevant non-major (CRNM) and minor bleeding. All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRMN bleeding were classified as minor bleeding.
| participants | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| Number of Participants With Adjudicated All Bleeding Events During the Treatment Periods | 7 | 17 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban | — | 3/40 (7.5%) | 29/40 (72.5%) |
| Unfractionated Heparin (UFH)/Warfarin | — | 7/39 (17.9%) | 34/39 (87.2%) |
| Event | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| Angina unstableCardiac disorders | 0/40 | 1/39 |
| CystitisInfections and infestations | 0/40 | 1/39 |
| PneumoniaInfections and infestations | 0/40 | 1/39 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 1/39 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 1/39 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 1/39 |
| Thalamus haemorrhageNervous system disorders | 0/40 | 1/39 |
| MenorrhagiaReproductive system and breast disorders | 0/40 | 1/39 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/40 | 1/39 |
| Deep vein thrombosisVascular disorders | 0/40 | 1/39 |
| Event | Apixaban | Unfractionated Heparin (UFH)/Warfarin |
|---|---|---|
| ConstipationGastrointestinal disorders | 5/40 | 8/39 |
| PyrexiaGeneral disorders | 4/40 | 5/39 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 3/40 | 5/39 |
| NasopharyngitisInfections and infestations | 5/40 | 4/39 |
| CystitisInfections and infestations | 1/40 | 4/39 |
| ContusionInjury, poisoning and procedural complications | 2/40 | 4/39 |
| FallInjury, poisoning and procedural complications | 4/40 | 4/39 |
| InsomniaPsychiatric disorders | 4/40 | 4/39 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 1/40 | 4/39 |
| NauseaGastrointestinal disorders | 1/40 | 3/39 |
All participants including one participant who was assigned to the UFH/Warfarin group and withdrew from the study prior to receiving any study medication.
| Age, Continuous(years) | Apixaban | Unfractionated Heparin (UFH)/Warfarin | Total |
|---|---|---|---|
| Mean | 64.3 ± 13.40 | 66.1 ± 17.72 | 65.2 ± 15.64 |
| Sex: Female, Male(Participants) | Apixaban | Unfractionated Heparin (UFH)/Warfarin | Total |
|---|---|---|---|
| Female | 18 | 23 | 41 |
| Male | 22 | 17 | 39 |
| Primary Diagnosis, Deep Venous Thrombosis (DVT)/Pulmonary Embolism (PE)(participants) | Apixaban | Unfractionated Heparin (UFH)/Warfarin | Total |
|---|---|---|---|
| DVT | 22 | 23 | 45 |
| PE | 18 | 17 | 35 |
The record gives a start of Jan 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban